Immucell financials
$9.94+0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.2M | $10.4M | $7.6M | $5.5M | $6.4M | $8.1M | $7.8M | $6.0M | $5.5M | $7.3M | $5.1M | $5.4M |
| Gross profit | $2.4M | $4.7M | $2.9M | $2.4M | $2.8M | $3.4M | $2.8M | $1.6M | $1.2M | $2.3M | $1.3M | $1.3M |
| Gross margin | 33.9% | 45.0% | 38.2% | 42.9% | 43.7% | 41.6% | 36.5% | 26.3% | 22.5% | 31.6% | 24.7% | 23.5% |
| Operating income | $1.9M | $2.0M | -$58.0K | $20.1K | $569.6K | $1.1M | $621.4K | -$574.9K | -$1.4M | -$300.1K | -$1.0M | -$1.2M |
| Net income | $1.8M | $1.9M | -$2.8M | -$139.7K | $501.9K | $1.4M | $514.6K | -$701.7K | -$1.5M | -$437.9K | -$1.1M | -$940.0K |
| Net margin | 25.5% | 18.7% | −37.4% | −2.5% | 7.8% | 17.9% | 6.6% | −11.7% | −28.0% | −6.0% | −22.4% | −17.4% |
| Diluted EPS | $0.20 | $0.21 | $-0.31 | $-0.02 | $0.06 | $0.16 | $0.06 | $-0.09 | $-0.20 | $-0.06 | $-0.15 | $-0.12 |
| EBITDA | $2.4M | $2.5M | $648.4K | $699.2K | $1.2M | $1.8M | $1.3M | $100.2K | -$715.6K | $367.2K | -$328.6K | -$483.6K |
| Operating cash flow | $3.0M | $3.6M | $482.5K | -$1.2M | $1.6M | $1.6M | -$3.1K | -$639.3K | $581.8K | $418.5K | -$723.1K | -$507.8K |
| Free cash flow | $2.3M | $3.4M | $310.2K | -$1.8M | $1.4M | $1.2M | -$199.3K | -$727.7K | $471.0K | $348.1K | -$804.4K | -$928.3K |
| Diluted shares | 9.2M | 9.0M | 9.0M | 9.0M | 9.0M | 9.0M | 8.9M | 8.2M | 7.8M | 7.8M | 7.8M | 7.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.9M | $6.8M | $3.8M | $3.9M | $6.0M | $4.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $8.3M | $8.7M | $9.1M | $9.5M | $9.8M | $10.2M |
| Total assets | $46.6M | $44.1M | $42.5M | $45.7M | $46.7M | $45.6M |
| Total liabilities | $15.3M | $15.0M | $15.5M | $15.9M | $16.9M | $16.6M |
| Shareholders' equity | $31.4M | $29.1M | $27.1M | $29.8M | $29.9M | $29.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology